
Summit Biomedical Imaging develops targeted fluorescent biomarkers that help clinicians find and remove cancer more effectively.


Summit Biomedical Imaging's fluorescent biomarkers detect and visualize PARP-overexpressing cancers, enabling clinicians to identify and remove tumors with precision.

Our biomarkers bind specifically to PARP, an enzyme overexpressed in many cancers, providing targeted detection and visualization.

Clinicians visualize tumor margins in real time during surgery, improving precision in cancer removal and reducing healthy tissue damage.

Fluorescent biomarkers reveal cancerous lesions that may be invisible to standard imaging, enabling earlier detection and more complete tumor removal.

Biomarker fluorescence guides surgeons to identify tumor margins, allowing for complete resection while preserving surrounding healthy tissue.

Summit's fluorescent biomarkers work across various cancer types with PARP overexpression, expanding clinical utility and patient benefit.

Complete tumor visualization during surgery leads to better resection, fewer recurrences, and improved survival rates for cancer patients.

Connect with our team to explore fluorescent biomarker solutions tailored to your oncology needs and patient outcomes.